Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda

DPSP

This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes compared to IPTp with SP alone or DP alone. This double-blinded randomized controlled phase III trial of 2757 HIV uninfected pregnant women enrolled at 12-20 weeks gestation will be randomized in equal proportions to one of three IPTp treatment arms: 1) SP given every 4 weeks, or 2) DP given every 4 weeks, or 3) SP+DP given every 4 weeks. SP or DP placebos will be used to ensure adequate blinding is achieved in the study and follow-up will end 28 days after giving birth.

2020-12-28

2024-06-01

2024-06-01

Active (not recruiting)

Early phase I

2757

Inclusion Criteria: 1. Viable singleton pregnancy confirmed by ultrasound 2. Estimated gestational age between 12-20 weeks 3. Confirmed to be HIV- uninfected by rapid test 4. 16 years of age or older 5. Residency within Busia District of Uganda 6. Provision of informed consent 7. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol 8. Willing to deliver in the hospital Exclusion Criteria: 1. History of serious adverse event to SP or DP 2. Active medical problem requiring inpatient evaluation at the time of screening 3. Intention of moving outside of Busia District Uganda 4. Chronic medical condition requiring frequent medical attention 5. Prior chemopreventive therapy or any other antimalarial therapy during this pregnancy 6. Early or active labor (documented by cervical change with uterine contractions) 7. Multiple pregnancies (i.e. twins/triplets)

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'Double blinded randomized controlled trial', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'Placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo or SP and DP) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. A randomization list will be computer generated by a member of the project who will not be directly involved in the conduct of the study. The randomization list will include consecutive treatment numbers with corresponding random treatment assignments. Randomized codes will correspond to the 3 treatment arms using permuted variable sized blocks of 6 and 9.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 2757, 'type': 'ACTUAL'}}

2024-03-19